April 8, 2015—The Health Resources and Services Administration took a step this morning toward launching a long-delayed system of civil fines for drugmakers that deliberately overcharge for 340B drugs, plus guidance on the calculation of 340B ceiling prices.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)